Skip to main content

Table 3 Weaning Schedule for Study Sildenafil or Placebo in Cohorts 2 and 3

From: Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study

Weaning Days IV Enteral
1–2 75% of last study dose 75% of last study dose
3–4 50% of last study dose 50% of last study dose
5–6 25% of last study dose 25% of last study dose
7 Discontinue Discontinue
  1. Abbreviation: IV intravenous